Connect with us

World News

EU approves Merck’s COVID-19 pill after treatments showed to reduce the risk of hospitalization and death in at-risk patients

Published

on

The European Union has approved Merck’s Covid-19 pill after showing it reduces the risk of hospitalization and death in at-risk patients.

Why Was Merck’s COVD-19 Pill Approved By EU?

The European Medicines Agency (EMA) on Friday made this announcement saying that they have given approval in the European Union of Merck’s COVID-19 pill for emergency use, although it has not yet received full marketing authorization.

Pfizer Anticovid Pill On Evaluation

On the other hand, it launched the evaluation of Pfizer’s anticovid pill, in the context of a new wave of infections in Europe.

These treatments from two US pharmaceutical giants are highly anticipated because studies indicate that they reduce the risk of hospitalization and death in at-risk patients.

The EMA said that although Merck’s pill had not yet been approved, it had “issued recommendations” so that the different countries of the European Union could decide on its use in case of a spike in infections.

Member states will be able to use it for the time being “to treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of developing a severe form” of the disease, the EMA said in a statement.

“The EMA has issued this opinion to support national authorities who can decide on a possible early use of the drug before marketing authorization, for example in emergency situations,” said the regulator.

However, the Merck pill should not be used by pregnant women or by women who do not use contraception and may become pregnant, according to the EMA.

The recommendations are explained because high doses of the Merck pill “may have an impact on the growth and development of the fetus,” according to studies, the agency said.

Advertisement

SPORTS

ENTERTAINMENT

HOT NOW!